- Home
- CHY vs GERN Comparison
CHY vs GERN Comparison
Compare CHY & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHY | GERN |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 911.0M |
| IPO Year | 2003 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHY | GERN |
|---|---|---|
| Price | $12.55 | $1.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 187.8K | ★ 8.1M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.41 | $1.04 |
| 52 Week High | $13.91 | $2.01 |
Technical Indicators
Market Signals| Indicator | CHY | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 41.90 |
| Support Level | $12.03 | $1.24 |
| Resistance Level | $13.55 | $1.46 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 19.73 | 6.52 |
Price Performance
Historical ComparisonAbout CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.